Pay in 4 interest-free payments of $5.95 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
A study published in the Endocrine Journal found a 266% increased risk of DVT for people taking semaglutide drugs
doi:10.3390/ijms23020739 199
This triple-agonist mechanism targets GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors, creating synergistic effects that outperform conventional single-target medications
This significantly strengthens the livers overall detoxification capacity, helping protect liver cells from liver oxidative stress induced by toxins and supporting efficient metabolic function
US$ 22.69
US$ 28.38
US$ 20.77
US$ 23.02
